What is Contineum Therapeutics, Inc. Class A Common Stock's Enterprise Value?

Contineum Therapeutics, Inc. Class A Common Stock's Enterprise Value is $554.9M, based on as-reported figures from SEC (XBRL) filings.

What is Contineum Therapeutics, Inc. Class A Common Stock's Net Income (TTM)?

Contineum Therapeutics, Inc. Class A Common Stock's Net Income (TTM) is -$57.6M, based on as-reported figures from SEC (XBRL) filings.

What is Contineum Therapeutics, Inc. Class A Common Stock's Diluted EPS (TTM)?

Contineum Therapeutics, Inc. Class A Common Stock's Diluted EPS (TTM) is -1.53, based on as-reported figures from SEC (XBRL) filings.

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Financial Statements

Contineum Therapeutics, Inc. Class A Common Stock

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG01M27SWR2

XNAS · usd

15.14▼ 0.80 (-5.02%)

As of 2026-09-09

Valuation

Market Cap

Enterprise Value

Trailing P/E—

Price / Sales—

EV / Revenue—

EV / EBITDA

Financial Highlights

Revenue (TTM)—

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin—

Net Debt

Trading Information

Previous Close15.94

Day's Range15.09 – 16.06

52-Week Range8.60 – 17.79

Volume388.8K

Avg Volume487.4K

Share Statistics

Shares Outstanding

Employees51

ExchangeXNAS

Listed2024-04-05

Share count as of July 24, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

What is Contineum Therapeutics, Inc. Class A Common Stock's Market Cap?: Contineum Therapeutics, Inc. Class A Common Stock's Market Cap is $569.6M, based on as-reported figures from SEC (XBRL) filings.
What is Contineum Therapeutics, Inc. Class A Common Stock's Enterprise Value?: Contineum Therapeutics, Inc. Class A Common Stock's Enterprise Value is $554.9M, based on as-reported figures from SEC (XBRL) filings.
What is Contineum Therapeutics, Inc. Class A Common Stock's EV / EBITDA?: Contineum Therapeutics, Inc. Class A Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Contineum Therapeutics, Inc. Class A Common Stock's Net Income (TTM)?: Contineum Therapeutics, Inc. Class A Common Stock's Net Income (TTM) is -$57.6M, based on as-reported figures from SEC (XBRL) filings.
What is Contineum Therapeutics, Inc. Class A Common Stock's EBITDA?: Contineum Therapeutics, Inc. Class A Common Stock's EBITDA is -$66.0M, based on as-reported figures from SEC (XBRL) filings.
What is Contineum Therapeutics, Inc. Class A Common Stock's Diluted EPS (TTM)?: Contineum Therapeutics, Inc. Class A Common Stock's Diluted EPS (TTM) is -1.53, based on as-reported figures from SEC (XBRL) filings.
What is Contineum Therapeutics, Inc. Class A Common Stock's Net Debt?: Contineum Therapeutics, Inc. Class A Common Stock's Net Debt is -$14.7M, based on as-reported figures from SEC (XBRL) filings.